Key Points
ALNA stock gains 3.16% to $0.075 in pre-market with 252M shares traded.
Allena Pharmaceuticals faces negative earnings and cash burn despite adequate liquidity.
Meyka AI rates ALNA as C+ HOLD based on comprehensive financial analysis.
Company focuses on rare kidney disorder treatment with ALLN-346 pipeline candidate.
Allena Pharmaceuticals, Inc. (ALNA) gained 3.16% in pre-market trading on May 5, 2026, climbing to $0.075 per share on the NASDAQ. The biotech company saw massive trading volume of 252.3 million shares, signaling strong investor interest despite ongoing challenges. ALNA stock has faced significant headwinds over the past year, declining 81.39% annually. The Newton, Massachusetts-based firm focuses on oral enzyme therapeutics for rare kidney and metabolic disorders. Its lead candidate, ALLN-346, targets hyperuricemia and gout in advanced chronic kidney disease patients. Today’s pre-market movement reflects the volatile nature of early-stage biotech stocks trading on thin liquidity.
ALNA Stock Performance and Trading Activity
ALNA stock opened at $0.0641 and reached a day high of $0.1459 before settling near $0.075 in pre-market action. The stock moved $0.0023 higher from the previous close of $0.0727. Trading volume exploded to 252.3 million shares, far exceeding typical daily activity levels.
This surge in volume suggests institutional or retail accumulation despite the stock’s troubled history. The day’s low of $0.06 shows buyers defending support levels. Track ALNA on Meyka for real-time updates on price movements and volume trends throughout the trading session.
Financial Health and Key Metrics
Allena Pharmaceuticals faces significant financial headwinds reflected in its key metrics. The company reported a negative earnings per share of -$0.638 and a price-to-earnings ratio of -0.12, indicating ongoing losses. Net income per share stands at -$1.03, while free cash flow per share is -$1.43, showing the company burns cash to fund operations.
On the positive side, ALNA maintains a current ratio of 2.11, suggesting adequate short-term liquidity to cover obligations. Cash per share totals $0.92, providing runway for research and development. The company’s book value per share is $0.58, with a price-to-book ratio of just 0.13, indicating the stock trades well below tangible asset value.
Meyka AI Stock Grade and Market Sentiment
Meyka AI rates ALNA with a grade of C+ based on a comprehensive scoring model. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The overall score of 58.98 suggests a HOLD recommendation for investors evaluating the stock.
The biotech sector remains volatile, and ALNA’s pre-market strength reflects speculative trading rather than fundamental improvement. The company’s three-year decline of 96.79% and ten-year loss of 99.25% highlight the challenges facing early-stage drug developers. These grades are not guaranteed and we are not financial advisors.
Company Overview and Pipeline Focus
Allena Pharmaceuticals operates as a biopharmaceutical company headquartered in Newton, Massachusetts, with approximately 120 full-time employees. The firm was incorporated in 2011 and went public in November 2017. The company specializes in discovering and commercializing oral enzyme therapeutics for patients with rare metabolic and kidney disorders.
ALLN-346 represents the company’s lead product candidate, targeting a niche market of gout patients with advanced chronic kidney disease. This rare disease focus limits addressable market size but reduces competition. The company’s strategy centers on developing treatments where few alternatives exist, positioning it within the biotechnology sector’s high-risk, high-reward investment profile.
Final Thoughts
ALNA’s 3.16% pre-market gain reflects biotech volatility, not fundamental strength. The stock is deeply distressed with 81.39% annual decline and negative earnings, though it maintains adequate liquidity. High trading volume suggests speculation. Meyka AI’s C+ grade indicates a HOLD for risk-averse investors. Short-term traders may be attracted, but long-term investors should wait for ALLN-346 clinical trial results before investing. Biotech requires patience and pipeline conviction.
FAQs
Pre-market moves in penny stocks typically reflect low liquidity and speculative trading rather than news catalysts. ALNA’s high volume suggests algorithmic or retail accumulation, with biotech stocks inherently volatile.
ALLN-346 is Allena’s lead candidate, a novel urate-degrading enzyme targeting hyperuricemia and gout in advanced chronic kidney disease patients. This rare disease focus reduces competitive pressure and regulatory complexity.
Meyka AI rates ALNA as a HOLD with a C+ grade. The stock trades below book value, but negative earnings and cash burn present risks. Evaluate clinical trial progress and cash runway before investing.
ALNA maintains $0.92 cash per share and a 2.11 current ratio, indicating adequate liquidity. However, negative free cash flow of -$1.43 per share means the company burns cash funding operations and research.
ALNA stock declined 81.39% over the past year and 99.25% over ten years, reflecting early-stage biotech challenges. The unprofitable company relies on cash reserves to fund operations and clinical trials.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)